Home' Australian Pharmacist : Australian Pharmacist June 2015 Contents Australian Pharmacist June 2015 I ©Pharmaceutical Society of Australia Ltd.
Items in the Product news section are prepared from information provided by the companies named in each
item. They are included for the information of PSA members. It is up to the individual member to use their
professional judgment to decide on the merit or otherwise of each product mentioned. PSA neither endorses
nor confirms claims made in the items. (Where provided by the company references citing evidence are
included with the items.)
Australian Pharmacist is a professional journal. It will carry only advertising which is likely to be of interest to all
pharmacists and which does not reflect unfavourably directly or by implication on the pharmacy profession or
the professional practice of pharmacy. Advertising which does not comply with this policy will be refused. It is
the responsibility of the advertisers to comply with the relevant Commonwealth and State law. Advertising does
not constitute an endorsement by PSA of the claims, products or services.
Read in greater detail more regularly than any other pharmacy title –
such constant behaviour means you can count on our readers to open
any issue and be seen!
» Greatest number of recipients opening and reading (82%)
» Greatest number of readers reading every issue (48%)
Engage with almost 18,800 PSA members every month (15,500
pharmacists in print and 16,000 in digital form).
» Australian Pharmacist is read by 65% of community pharmacists
It has an extremely strong CPD program followed by more than 10,000
pharmacists – a typical monthly article receives 3000 plus assessments,
with highs over 4000!
» Greatest average proportion read (73%)
» Circulation 14,872 cab March 2013
TO ADVERTISE in the best-read pages in pharmacy media and give your campaign real
impact, and greater recognition, contact Tremain Media.
Ph: 02 9988 4689
Ph: 02 9547 3001
Ph: 02 9871 5520
*Competitive Advantage Research August 2012 – 632 practicing community pharmacists
Answers for crossword on page 67.
Across: 1. Nausea, 7. Got, 8. Fatal,
9. Any, 11. Flat, 13. Hallucination,
14. Seal, 15. Dread, 19. Antipsychotic,
21. Clozapine, 22. Adverse, 23. Amid.
Down: 2. SGA, 3. Eon, 4. Atypical,
5. Caffeine, 6. Acute, 10. Delusion,
12. Cardiac, 16. Delirium, 17. NMS,
18. Divide, 19. Alpha, 20. Oral, 21. CNS.
Bristol‐Myers Squibb (BMS) has
announced that Ye r v o y (ipilimumab
3mg/kg) is registered on the Therapeutic
Goods Administration (TGA) – and
available through the Pharmaceutical
Benefits Scheme (PBS) – for first line
treatment of adult patients with advanced
(unresectable or metastatic) melanoma,
the most serious form of skin cancer.
According to BMS this means that
Australians with newly diagnosed
advanced melanoma will be eligible to
receive Ye r v o y as their first treatment,
independent of mutational status.
This provides prescribers with more
treatment options. Importantly, it also
means that patients can be treated
with the recommended four infusions
of Yervoy earlier in the course of their
disease. Completing the recommended
four infusions has been shown to
improve the survival benefit for
patients.3 Dr Megan Lyle, Specialist
Medical Oncologist at the Liz Plummer
Cancer Centre, Cairns Hospital said:
‘Advanced melanoma is one of the most
aggressive forms of cancer. Historically,
patients with advanced melanoma had
an average life expectancy of between
six to nine months.
Yervoy is the first
registered treatment to demonstrate
long‐term survival in some patients.
Oncologists can now offer patients the
chance to access this potential benefit
when they are newly diagnosed with
Ten year survival data shows the
durability of long‐term survival in
melanoma patients treated with Ye r v o y .
1. Schadendorf et al. Pooled Analysis of Long-Term survival
data from phase II and phase III trials of ipilimumab in
unresectable or metastatic melanoma. J Clin Oncol
2. Melanoma Institute of Australia. At: www.melanoma.
(accessed 18 Mar 2015.)
3. Eigentler et al. Effectiveness ad Tolerability of Ipilimumab:
Experiences from 198 Patients Included in a Named-
Patient Program in Various Daily-Practice Settings and
Multiple Institutions. J Immunother 2014 Sep;37(7)
4. Korn El et al. (2008). Meta-analysis of phase II cooperative
trials in metastatic stage IV melanoma to determine
progression-free survival benchmarks for future phase II
trials. J Clin Oncol. 2008;1(26):4:527–34
Trusted pharmacy‐only brand Faulding
has released the Faulding WoundCare+
range which uses moist wound healing
technology, to promote faster healing
and minimises scarring. According to
Faulding, allowing wounds to dry out
can often result in scab formation and
scarring while moist wound conditions
assist in the development of new blood
vessels in the injured tissue, creating a
better healing result.
The new range consists of five individual
wallets for specific wound types.
This includes: Grazes + Abrasions, Blisters,
Superficial Burns, Cuts + Lacerations and
Finger Injuries, as well as a new product –
the Finger Bob. The Finger Bob is suitable
for all fingers and secures a wound
dressing in a matter of seconds. Executive
Director at Endeavour Consumer
Health, Jennifer Luke, said: ‘Endeavour
Consumer Health identified the wound
care category as an ideal opportunity for
Faulding to provide consumers with more
health management solutions.
Links Archive Australian Pharmacist May 2015 Australian Pharmacist July 2015 Navigation Previous Page Next Page